心血管疾患治療薬の創薬動向：2008年

This market analysis provides an unparalleled comparative study of key research in 6 leading cardiovascular market sectors, unique and original market forecasts and critical analyses and competitive ratings for upcoming products.

Cardiovascular disease is a global problem. In the developed world, its prevalence is linked to our increasingly unhealthy lifestyle, with risk factors including lack of exercise, overweight and obesity, and smoking. These are also linked to diabetes which increases the risk of developing heart disease.

The global desire for cheaper generic drugs has been putting increasing pressure on the research-based industry, which finds itself having to defend its patents in the courts to ward off generic competition for as long as possible. Legal battles are won and lost on both sides; either way, patents eventually expire and generic competition is inevitable.

But what of the future? Opportunities for new therapies exist in both main and niche markets - the latter being relatively uncompetitive and where there is high unmet clinical need, such as pulmonary arterial hypertension.

Among the market leaders, several will lose, or have recently lost, patent protection in major markets over the next few years. The resulting loss in revenue for the research-based industry can be dramatic.

For example, following peak sales of US$5,580 million in 2002, Merck & Co' s Zocor (simvastatin) lost its basic patent protection in Canada and a number of countries in Europe, including the UK and Germany in 2003. Sales subsequently declined in these countries as a result of generic competition.

The US patent on Zocor finally expired on 23rd June 2006, following six months paediatric extension. The FDA approved two generics with 180-days market exclusivity, resulting in a downturn in sales of Zocor to US$2.8 billion for the full year. The entry of multiple generics onto the market from December 2006, however, resulted in a dramatic fall in sales of Zocor in 2007, to US$876 million. The effect of generic simvastatin was not, however, confined to Zocor but rippled through the market, impacting sales of Pfizer' s Lipitor (atorvastatin) in the short term.

• Unique sales forecasts for key new and current products to 2012
• A comprehensive examination of 6 major cardiovascular therapy areas
• Critical analyses and competitive ratings for current and upcoming products

• Cholesterol and Triglycerides
• Hypertension
• Coronary Artery Disease
• Pulmonary Arterial Hypertension
• Atrial Fibrillation
• Thrombosis

• Foreword
• Executive Summary
• Cardiovascular Disease
• Mortality
• Prevention and Treatment
  • Drugs in the Pipeline
  • Competitor Ratio Analysis
• Cholesterol and Triglycerides
• The Cholesterol Management Drugs Market
• Statins
  • NICE Guidance on the use of statins
  • Lipitor (atorvastatin)
    • Patents, Generic Competition & Litigation
      • US
      • Canada
      • Austria
      • Denmark
      • Finland
      • Ireland
      • Norway
      • Spain
      • UK
      • Australia
      • Andean Pact countries
    • Sales Forecast
    • Clinical Trials
      • SPARCL
      • Imaging studies: ILLUSTRATE and RADIANCE
      • Pfizer' s response to the ASTEROID trial
      • TNT
      • ASCOT
      • ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial: Lipid-Lowering Arm)
      • CARDS
      • IDEAL - atorvastatin versus simvastatin
      • Atorvastatin+rosiglitazone in diabetic patients
• Lescol (fluvastatin)
  • Patents & Generic Competition
  • Sales Forecast
  • Clinical Trials
    • ALERT
    • LIPS
• Crestor (rosuvastatin)
  • Patents, Generic Competition & Litigation
  • Safety Issues
  • Patient data demonstrate efficacy of Crestor
  • Sales Forecast
  • Clinical Trials
    • ASTEROID
    • METEOR
    • MERCURY II
    • EXPLORER
    • Effect of rosuvastatin on C-reactive protein and renal function
    • Crestor in combination with ezetimibe
    • LDL-C reductions - Crestor versus Pravachol and Zocor
• Zocor (simvastatin)
  • Generic Competition
  • Sales Forecast
  • Clinical Trials
    • SAFARI - simvastatin+fenofibrate
    • 4S
    • Heart Protection Study
• Other Antihyperlipidaemic Agents
  • Zetia (ezetimibe)
    • NICE guidance on ezetimibe
  • Patents, Generic Competition & Litigation
  • Sales Forecast
  • Clinical Trials
    • EXPLORER
    • Co-administration of ezetimibe+fenofibrate
    • EASE
  • TriCor (fenofibrate)
    • Patents, Litigation & Generic Competition
      • Lipofen (fenofibrate)
      • Fenoglide (fenofibrate)
  • Sales Forecast
  • Clinical Trials
    • TriCor (fenofibrate) & WelChol (colesevelam)
• Niaspan (niacin)
  • Patents & Litigation
  • Sales Forecast
  • Clinical Trials
    • Niaspan combined with aspirin
    • COMPELL
• Combination Products
  • Vytorin (ezetimibe+simvastatin)
    • FDA issues early communication regarding ongoing review of Vytorin
  • Patents
  • Sales Forecast
  • Clinical Trials
    • ENHANCE
    • IMPROVE-IT
    • Vytorin versus Lipitor (atorvastatin) in Type II diabetes patients
    • Combined post hoc analysis of three studies
    • VYVA
  • Caduet (amlodipine+atorvastatin)
  • Patents & Generic Competition
  • Sales Forecast
  • Clinical Trials
    • GEMINI AALA
    • JEWEL
• Recent Approval and Drugs in Development
  • Simcor
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
    • Sales Forecast
    • Clinical Trials
      • SEACOAST
  • Tredaptive (niacin+laropiprant)
    • Competitor ratio analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • Phase III
    • Tredaptive co-administered with simvastatin
• MK-0524B (simvastatin+niacin+laropiprant)
  • Competitor ratio analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace
    • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • MK-0452B versus atorvastatin
    • MK-0452B versus MK-0452A+simvastatin
• TriLipix (ABT-335)
  • Competitor ratio analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace
    • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
• Anacetrapib
  • Competitor ratio analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace
    • Risks associated with drug development in therapeutic class
  • Outlook
  • Clinical Trials
    • Phase IIb
    • Phase I
  • AEGR-733
    • Competitor ratio analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
  • Outlook
  • Clinical Trials
    • Phase II
    • Homozygous Familial Hypercholesterolaemia
• Hypertension
• The Hypertension Drugs Market
• Angiotensin-II Receptor Blockers
  • Aprovel (irbesartan)
    • Patents & Generic Competition
    • Sales Forecast
    • Clinical Trials
      • INCLUSIVE
      • COSIMA
  • Diovan/Co-Diovan (valsartan/valsartan+HCTZ)
    • Patents, Generic Competition & Litigation
    • Sales Forecast
    • Clinical Trials
      • NAVIGATOR
      • AADVANCE
      • VALUE
      • Val-HeFT
  • Cozaar/Hyzaar (losartan/losartan+HCTZ)
    • Patents & Generic Competition
    • Sales Forecast
    • Clinical Trials
      • LIFE
      • ELITE II
  • Micardis/MicardisPlus (telmisartan/telmisartan+HCTZ)
    • Patents & Generic Competition
    • Sales Forecast
    • Clinical Trials
      • SURGE-2
      • PRISMA
      • ONTARGET/TRANSCEND
      • PROTECTION
      • PROTECTION Study Programme - AMADEO
      • PROTECTION Study Programme - DETAIL
      • PROTECTION Study Programme - ESPRIT
      • PROTECTION Study Programme - ATHOS
      • PROTECTION Study Programme - INNOVATION
• Atacand (candesartan cilexetil)
  • Patents & Generic Competition
  • Sales Forecast
  • Clinical Trials
    • HIJ-CREATE
    • TROPHY
    • CHARM
    • DIRECT
    • Switching from losartan to candesartan cilexetil: an observational study in the UK
  • Benicar (olmesartan)
    • Patents & Generic Competition
    • Sales Forecast
    • Clinical Trials
      • MORE
      • BEST & Treatment of Stage I and Stage II Hypertension Studies
• Dihydropyridine Calcium Channel Blockers
  • Norvasc (amlodipine)
    • Patents & Generic Competition
    • Sales Forecast
    • Clinical Trials
      • ASCOT
      • CAFE
  • Adalat (nifedipine)
    • Patents & Generic Competition
    • Sales Forecast
    • Clinical Trials
      • TALENT
      • ACTION
  • Zanidip (lercanidipine)
    • Sales Forecast
• ACE Inhibitors
  • Vasotec (enalapril)
    • Generic Competition
    • Sales Forecast
  • Altace/Delix/Tritace (ramipril)
    • Combinations
    • Patents & Generic Competition
  • Sales Forecast
  • Clinical Trials
    • Altace+HCTZ
• Beta Blockers
  • Coreg (carvedilol)
    • OPTIMIZE-HF
  • Patents & Generic Competition
  • Sales Forecast
  • Clinical Trials
    • MUCHA
    • COMET
    • COPERNICUS
• Seloken/Toprol-XL (metoprolol succinate)
  • Patents & Generic Competition
  • Sales Forecast
  • Clinical Trials
    • POISE
• Alpha Adreno-Receptor Antagonists
  • Cardura (doxazosin)
    • Sales Forecast
  • Combination Products
    • Lotrel (amlodipine+benazepril)
      • Patents & Generic Competition
      • Sales Forecast
      • Clinical Trials
        • ACCOMPLISH
        • LOGIC, SHIELD and ALERT
    • Azor (amlodipine+olmesartan)
    • Zanipress (lercanidipine+enalapril)
• Recent Approvals and Drugs in Development
  • Rasilez/Tekturna (aliskiren)
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace
    • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • ALLAY
    • Phase III Results
    • Phase II Results
• Bystolic (nebivolol)
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace
    • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • Bystolic in African-American patients with Stage I-II HT
    • Patients with mild-to-moderate HT
• Darusentan
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace
    • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • DAR-201
  • Cleviprex (clevidipine)
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
    • Sales Forecast
    • Clinical Trials
      • VELOCITY
      • ECLIPSE
    • Ilepatril
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
    • Coronary Artery Disease
      • Genetic variations may increase risk of CAD
  • Angina
  • Recent Approvals and Drugs in Development
    • Crestor: first statin to achieve atherosclerosis regression by QCA in a major clinical trial
• Ranexa (ranolazine)
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within marketplace
    • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • Ranolazine in LQT3
    • MERLIN TIMI-36
    • ERICA
    • CARISA
    • MARISA
• Procoralan (ivabradine)
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within marketplace
    • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • Procoralan versus amlodipine in patients with stable CAD
    • BEAUTIFUL
• Generx (alferminogene tadenovec, Ad5FGF-4)
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace
    • Risks associated with drug development in therapeutic class
  • Clinical Trials
    • AWARE
    • AGENT-3, AGENT-4
  • Experimental Stem Cell Therapy
• Atrial Fibrillation
• Current Treatments
  • Cordarone (amiodarone)
  • Rythmol (propafenone)
  • Tambocor (flecainide)
  • Corvert (ibutilide fumarate)
  • Tikosyn (dofetilide)
    • Clinical Trials
      • DIAMOND
• Drugs in Development
  • Multaq (dronedarone)
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
    • Sales Forecast
    • Clinical Trials
      • EURIDIS and ADONIS
  • Pulzium (tedisamil)
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
  • Sales Forecast
    • Clinical Trials
• Vernakalant (RSD1235)
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within marketplace
    • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • ACT 1
    • ACT 3
    • Phase IIb study of oral vernakalant
• Pulmonary Arterial Hypertension
  • Tracleer (bosentan)
  • Sales Forecast
  • Clinical Trials
    • COMPASS-1 and EARLY
    • BUILD Programme
    • BREATHE-5
    • Paediatric Study
    • TRAX PMS
• Ventavis (iloprost)
  • Sales Forecast
  • Clinical Trials
    • VISION
    • STEP
    • Long-term safety and efficacy
    • ACTIVE
• Revatio (sildenafil)
  • Sales Forecast
  • Clinical Trials
    • Australian Trial in Heart Failure
• Thelin (sitaxsentan)
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within marketplace
    • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • Eisenmenger syndrome - observational data
    • Long-term treatment
    • STRIDE-2
    • STRIDE-2X
    • STRIDE-4
• Letairis/Volibris (ambrisentan)
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace
    • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • ARIES
    • AMB-222
  • Viveta (treprostinil)
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace
    • Risks associated with drug development in therapeutic class
  • Clinical Trials
    • Treprostinil in AERx Essence delivery system
    • TRIUMPH-1
    • Inhaled treprostinil as add-on therapy
• Thrombosis
• Thrombosis Drugs Market
  • Lovenox (enoxaparin)
  • Patents & Generic Competition
  • Sales Forecast
  • Clinical Trials
    • ExTRACT-TIMI 25
    • STEEPLE
    • SYNERGY
• Arixtra (fondaparinux)
  • Patents & Generic Competition
  • Sales Forecasts
  • Clinical Trials
    • OASIS- 5
    • OASIS 6
    • ARTEMIS
    • FLEXTRA
    • PEGASUS
• Plavix (clopidogrel)
  • Patents & Generic Competition
  • Sales Forecast
  • Clinical Trials
    • Individualised loading study
    • BRAVE-3
    • CHARISMA
    • ACTIVE
• Recent Approval and Drugs in Development
  • Pradaxa (dabigatran)
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within the marketplace
      • Risks associated with drug development in therapeutic class
    • Sales Forecast
    • Clinical Trials
      • RE-VOLUTION (RE-MODEL, RE-MOBILIZE and RE-NOVATE)
  • Prasugrel
    • Competitor Ratio Analysis
      • Novelty/rationale for mechanism of action
      • Proof of concept/clinical data
      • Management/clinical expertise
      • Competition within marketplace
      • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • TRITON-TIMI 38
    • Early-phase data
• Rivaroxaban
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within marketplace
    • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • RECORD2
    • RECORD3
    • Phase ll studies
• Apixaban
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace
    • Risks associated with drug development in therapeutic class
  • Sales Forecast
  • Clinical Trials
    • Phase II
• M118
  • Competitor Ratio Analysis
    • Novelty/rationale for mechanism of action
    • Proof of concept/clinical data
    • Management/clinical expertise
    • Competition within the marketplace
    • Risks associated with drug development in therapeutic class
  • Clinical Trials
    • Phase II
    • Phase I
• Abbreviations
• SOURCES
• Espicom Sources
• Others

• Deaths from Ischaemic Heart Diseases in Selected Markets, 2005
• Deaths from Acute Myocardial Infarction in Major Markets, 2005
• Deaths from Diseases of the Pulmonary Circulation and Other Forms of Heart Disease, 2005
• Leading Cardiovascular Drugs by Sales Value, 2006-2007 (US$ Million)
• US Patent Expiry for Major Cardiovascular Drugs
• Launched Products in Development
• Novel Drugs in Development
• Competitor Ratio Analysis Summary
• Sales of Leading Cholesterol Management Drugs, 2006-2007 (US$ Million)
• Sales of Leading Statins, 2003-2007 (US$ Million)
• Lipitor Sales, 2003-2012 (US$ Million)
• Lipitor US Patents
• Lescol Sales, 2003-2007 (US$ Million)
• Lescol US Patents
• Crestor Sales, 2003-2007 (US$ Million)
• Crestor US Patents
• Zocor Sales, 2003-2007 (US$ Million)
• Zetia Sales, 2003-2007 (US$ Million)
• Zetia US Patents
• TriCor Sales, 2003-2007 (EUR & US$ Million)
• TriCor US Patents
• Niaspan Sales, 2003-2007 (US$ Million)
• Niaspan US Patents
• Vytorin Sales, 2004-2007 (US$ Million)
• Vytorin US Patents
• Caduet Sales, 2004-2007 (US$ Million)
• Caduet US Patents
• Drugs in Development for Hypercholesterolaemia and Dyslipidaemia
• Sales of Leading Hypertension Drugs, 2006-2007 (US$ Million)
• Aprovel/Avapro/Karvea Sales, 2003-2007 (EUR & US$ Million)
• Avapro/Avalide US Patents
• Diovan/Co-Diovan Sales, 2003-2007 (US$ Million)
• Diovan US Patents
• Cozaar/Hyzaar Sales, 2003-2007 (US$ Million)
• Cozaar/Hyzaar US Patents
• Micardis Sales, 2003-2007 (EUR & US$ Million)
• Micardis Sales in Japan, 2003-2007 (¥ & US$ Million)
• Micardis US Patents
• Atacand Sales, 2003-2007 (US$ Million)
• Blopress Sales, 2003-2007 (¥ Billion & US$ Million)
• Atacand/Atacand Plus US Patents
• Benicar/Olmetec Sales, 2004-2007 (¥ Million & US$ Million)
• Benicar US Patents
• Norvasc Sales, 2003-2007 (US$ Million)
• Amlodin Sales, 2003-2007 (¥ Billion & US$ Million)
• Adalat Sales, 2003-2007 (EUR & US$ Million)
• Adalat US Patents
• Zanidip Sales, 2003-2007 (EUR & US$ Million)
• Vasotec/Vaseretic Sales, 2003-2007 (US$ Million)
• Altace/Delix/Tritace Sales, 2003-2007 (EUR & US$ Million)
• Altace US Patents
• Coreg/Dilatrend Sales, 2003-2007 (£/CHF & US$ Million)
• Coreg US Patents
• Seloken ZOK/Toprol-XL Sales, 2003-2007 (US$ Million)
• Cardura Sales, 2003-2007 (US$ Million)
• Lotrel Sales, 2003-2007 (US$ Million)
• Lotrel US Patents
• Drugs in Development for Hypertension
• Drugs in Development for Atherosclerosis and Coronary Artery Disease
• Drugs in Development for Atrial Fibrillation
• Drugs in Development for PAH
• Tracleer Sales, 2003-2007 (CHF & US$ Million)
• Sales of Leading Anticoagulant & Antiplatelet Drugs, 2006-2007 (US$ Million)
• Lovenox/Clexane Sales, 2003-2007 (EUR & US$ Million)
• Lovenox US Patents
• Arixtra Sales, 2004-2007 (£ & US$ Million)
• Plavix/Iscover Sales, 2003-2007 (EUR & US$ Million)
• Plavix US Patents
• Drugs in Development for Thrombosis

• Global Sales of Leading Statins, 2003-2007 (US$ Million)
• Lipitor Sales, 2003A-2012E (US$ Million)
• Lescol Sales 2003A-2012E (US$ Million)
• Crestor Sales, 2003A - 2012E (US$ Million)
• Zocor Sales 2003A-2012E (US$ Million)
• Zetia Sales 2003A-2012E (US$ Million)
• TriCor Sales, 2003A-2012E (US$ Million)
• Niaspan Sales, 2003A - 2012E (US$ Million)
• Vytorin Sales, 2004A-2012E (US$ Million)
• Caduet Sales 2004A-2012E (US$ Million)
• Simcor Projected Sales, 2008-2012 (US$ Million)
• Tredaptive Projected Sales, 2008-2012 (US$ Million)
• MK-0524B Projected Sales, 2009-2013 (US$ Million)
• TriLipix Projected Sales, 2010-2013 (US$ Million)
• Aprovel/Avapro Sales 2003A-2012E (US$ Million)
• Diovan/Co-Diovan Sales 2003A-2012E (US$ Million)
• Cozaar/Hyzaar Sales 2003A-2012E (US$ Million)
• Micardis Sales, 2003A-2012E (US$ Million)
• Atacand Sales, 2003A-2012E (US$ Million)
• Blopress Sales, 2003A-2012E (¥ Billion)
• Benicar/Olmetec Sales 2003A-2012E (US$ Million)
• Norvasc Sales, 2003A- 2012E (US$ Million)
• Amlodin Sales, 2003A-2012E (¥ Billion)
• Adalat Sales 2003A-2012E (US$ Million)
• Zanidip Sales 2003A-2012E (US$ Million)
• Vasotec/Vaseretic Sales 2003A-2012E (US$ Million)
• Altace/Tritace Sales 2003A-2012E (US$ Million)
• Coreg Sales, 2003A-2012E (US$ Million)
• Seloken/Toprol-XL Sales 2003A-2012E (US$ Million)
• Cardura Sales 2003A-2012E (US$ Million)
• Lotrel Sales, 2003A-2012E (US$ Million)
• Rasilez/Tekturna Projected Sales, 2007-2012 (US$ Million)
• Bystolic Projected Sales, 2008-2013 (US$ Million)
• Darusentan Projected Sales, 2009-2012 (US$ Million)
• Cleviprex Projected Sales, 2008-2013 (US$ Million)
• Ranexa Sales 2006A-2012E (US$ Million)
• Procoralan Sales, 2006E-2012E (US$ Million)
• Multaq Projected Sales, 2009E-2014E (US$ Million)
• Pulzium Projected Sales 2008E-2013E (US$ Million)
• Kynapid Projected Sales 2008E-2013E (US$ Million)
• Tracleer Sales, 2003A-2012E (US$ Million)
• Ventavis Sales, 2005A-2012E (US$ Million)
• Revatio Sales, 2005A-2012E (US$ Million)
• Thelin Sales, 2006A-2012E (US$ Million)
• Letairis/Volibris Projected Sales, 2008-2012 (US$ Million)
• Lovenox Sales, 2003A-2012E (US$ Million)
• Arixtra Sales, 2004A-2012E (US$ Million)
• Plavix/Iscover Sales, 2003A-2012E (US$ Million)
• Pradaxa Projected Sales, 2008-2013 (US$ Million)
• Prasugrel Projected Sales, 2008-2013 (US$ Million)
• Rivaroxaban Projected Sales, 2009-2014 (US$ Million)
• Apixaban Projected Sales, 2010-2014 (US$ Million)